Anti-AAV5 Antibodies and ELISA Kits Reliable Detection for AAV5 Serology

Adeno-associated virus serotype 5 (AAV5) has emerged as one of the most promising viral vectors for human gene therapy. Its unique tropism for multiple tissues—including the liver, lung, central nervous system, and cardiac muscle—combined with its low immunogenicity profile compared to other serotypes, has made AAV5 a preferred vector for numerous clinical applications. AAV5-based therapeutics are currently being evaluated in clinical trials for hemophilia, Pompe disease, Parkinson's disease, and other genetic disorders. However, the successful development and clinical translation of AAV5-based gene therapies depend critically on accurate monitoring of host immune responses against the vector. Preexisting neutralizing antibodies (NAbs) and treatment-emergent anti-AAV5 antibodies can significantly reduce transduction efficiency, limit therapeutic efficacy, and pose patient safety risks. Reliable serological detection of anti-AAV5 antibodies is therefore essential for patient screening, dose stratification, and post-treatment monitoring.

Figure 1.Anti-AAV5 Antibodies and ELISA Kits.

Why Anti-AAV5 Detection Matters

Why Anti-AAV5 Detection Matters	Details
The Challenge of Preexisting Immunity	A major hurdle in AAV-based gene therapy is the high prevalence of preexisting neutralizing antibodies in the human population. For AAV5, seroprevalence rates vary geographically but typically range from 15% to 40% depending on the cohort. Individuals with preexisting anti-AAV5 NAbs may be ineligible for treatment or require higher vector doses, which increases the risk of adverse events. Accurate pre-screening using validated serological assays is therefore a regulatory requirement for most AAV5 gene therapy clinical trials.
Treatment-Emergent Antibodies	Even in seronegative patients, administration of AAV5 vectors often triggers the production of de novo anti-AAV5 antibodies. These treatment-emergent NAbs can preclude re-administration of the same vector, a critical consideration for diseases requiring repeated dosing. Longitudinal monitoring of anti-AAV5 antibody titers provides valuable data for understanding the durability of transgene expression and planning potential redosing strategies.
Preclinical Studies in Animal Models	In preclinical gene therapy research, mice are the most commonly used animal model. Detecting mouse anti-AAV5 antibodies following vector administration is essential for evaluating immunogenicity, optimizing dosing regimens, and predicting clinical outcomes. Reliable mouse-specific serological assays are therefore indispensable tools for translational research.

Product Overview: Anti-AAV5 Detection Solutions

To address the growing demand for accurate and reproducible anti-AAV5 serology, Creative Diagnostics offers a comprehensive portfolio of detection reagents and kits. Each product is rigorously validated for sensitivity, specificity, and lot-to-lot consistency.

Product	Target Species	Application
Human anti-AAV5 antibody ELISA Kit	Human	Patient screening,clinical trial monitoring
Mouse Anti-AAV5 antibody ELISA Kit	Mouse	Preclinical immunogenicity assessment
Anti-AAV5 (intact particle) monoclonal antibody	N/A	ELISA development, neutralizing antibody assays, immunohistochemistry

Human anti-AAV5 antibody ELISA Kit

The Human Anti-AAV5 Antibody ELISA Kit is designed for the quantitative or qualitative determination of total anti-AAV5 antibodies (IgG) in human serum, plasma, or other biological fluids. This kit is optimized for high-throughput screening applications in clinical research and regulatory-compliant environments.

Key Features

High Sensitivity: Detects anti-AAV5 antibodies at concentrations as low as 1 ng/mL, ensuring reliable identification of low-titer seropositive samples that may be missed by less sensitive methods.
Specificity Verified: No cross-reactivity with antibodies against other AAV serotypes (AAV1, AAV2, AAV3, AAV4, AAV6, AAV8, AAV9) or common viral pathogens.
Ready-to-Use Format: Pre-coated plates, pre-diluted standards, and concentrated reagents reduce hands-on time and minimize operator error.
Qualitative and Quantitative Options: Can be used for binary (positive/negative) patient screening or absolute quantification of antibody concentrations using a standard curve.

Mouse Anti-AAV5 antibody ELISA Kit

The Mouse Anti-AAV5 Antibody ELISA Kit is specifically designed for preclinical gene therapy studies using murine models. This kit enables researchers to assess the immunogenicity of AAV5-based vectors in mice, a critical parameter for vector optimization and dose selection.

Key Features

Species-Specific Detection: Uses secondary antibodies optimized for mouse IgG, eliminating cross-reactivity with other immunoglobulins.
Sample Compatibility: Validated for mouse serum, plasma, and cell culture supernatants.
Low Sample Volume Requirement: Requires as little as 10 µL of sample per well, conserving valuable material from small-volume mouse bleeds.
High Reproducibility: Rigorously tested for intra- and inter-assay precision, meeting the requirements of GLP-compliant preclinical studies.

Key Applications

ELISA Development: The antibody can be used as either a capture or detection reagent for in-house ELISA development. Its specificity for intact particles ensures that only full, functional capsids are detected, avoiding false positives from aggregated or degraded vector material.

Neutralizing Antibody Assays: When used in neutralization assays, this antibody serves as a positive control or as a tool for validating assay performance. It binds to AAV5 capsids in a conformation-dependent manner, blocking receptor binding and mimicking the effect of patient-derived NAbs.
Quality Control of AAV5 Vector Preparations: The antibody can be employed in ELISA or plate-based assays to quantify intact AAV5 particles in vector production lots, complementing physical titer methods such as qPCR or ddPCR.
Cellular Localization Studies: IHC and immunofluorescence applications allow researchers to visualize AAV5 particle distribution in cultured cells or tissue sections following vector administration.

Conclusions

Reliable detection of anti-AAV5 antibodies is a cornerstone of successful AAV5-based gene therapy development, from preclinical research through clinical trials and eventual commercialization. The human and mouse anti-AAV5 antibody ELISA kits provide validated, ready-to-use solutions for serological screening and immunogenicity monitoring, offering high sensitivity, specificity, and reproducibility. The anti-AAV5 intact particle monoclonal antibody serves as a versatile research reagent for ELISA development, neutralizing antibody assays, and capsid detection applications. Together, these products form a comprehensive toolkit for researchers and clinicians working with AAV5 vectors. Accurate serology not only enables patient selection and dose optimization but also advances our understanding of the immune response to AAV5, ultimately supporting the development of safer and more effective gene therapies.

Anti-AAV5 Antibodies ELISA Kits

Cat. No.	Product Name	Size	Species Reactivity	Application	Detection Method
DEIASL343	GTCDxᵀᴹ Anti-AAV5 Antibody ELISA Kit	96T	Human	Qualitative	iELISA	Inquiry
DEIASL343Y	GTCDxᵀᴹ Monkey Anti-AAV5 Antibody ELISA Kit	96T	Monkey	Qualitative	iELISA	Inquiry
DEIASL344Y	GTCDxᵀᴹ Monkey Anti-AAV6 Antibody ELISA Kit	96T	Monkey	Qualitative	iELISA	Inquiry
DEIASL347Y	GTCDxᵀᴹ Monkey Anti-AAV2 Antibody ELISA Kit	96T	Monkey	Qualitative	iELISA	Inquiry
DEIASL348Y	GTCDxᵀᴹ Monkey Anti-AAV9 Antibody ELISA Kit	96T	Monkey	Qualitative	iELISA	Inquiry

Anti-AAV5 Antibodies

Target	Cat. No.	Product Name	Host	Isotype	Application
AAV	DMAB-CS24200	Canine Anti-AAV5 Monoclonal antibody, clone Y506	Canine	IgG	ELISA	Inquiry
AAV	DMAB6354RP	Pig Anti-AAV5 (intact particle) monoclonal antibody, clone BEL6c	Pig	IgG	ELISA, Control	Inquiry
AAV	DMAB-CS24229R	Rabbit Anti-AAV5 (intact particle) Monoclonal antibody, clone BEL6b	Rabbit	IgG	ELISA	Inquiry